Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 2:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–46 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Talimogene laherparepvec Clear all
Completed Phase 1 Interventional Results available

Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer

NCT00402025
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Talimogene Laherparepvec
Biological
Lead sponsor
BioVex Limited
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
3
States / cities
Orange, California • San Francisco, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Sep 26, 2026, 2:12 PM EDT
Not listed Phase 1 Interventional

Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma

NCT03088176
View directory record Official record
Conditions
Melanoma, BRAF Gene Mutation
Interventions
Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil, Talimogene Laherparep 100 Mil Pfu/Ml 1Ml, Dabrafenib, Trametinib
Drug
Lead sponsor
West Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Germantown, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 11, 2020 · Synced Sep 26, 2026, 2:12 PM EDT
Terminated Phase 2 Interventional Results available

Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma

NCT03921073
View directory record Official record
Conditions
Angiosarcoma of Skin
Interventions
T-VEC
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Sep 26, 2026, 2:12 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion

NCT03597009
View directory record Official record
Conditions
Malignant Pleural Effusion, Stage IV Metastatic Cancer, Lung Cancer
Interventions
Talimogene laherparepvec (TVEC), Nivolumab
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Sep 26, 2026, 2:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

TVEC and Preop Radiation for Sarcoma (4 ml Dose)

NCT02453191
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Talimogene Laherparepvec, Radiotherapy
Drug · Radiation
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 19, 2024 · Synced Sep 26, 2026, 2:12 PM EDT
Completed No phase listed Observational

Registry Study for Talimogene Laherparepvec

NCT02173171
View directory record Official record
Conditions
Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial
Interventions
Information collection
Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
26
States / cities
Mobile, Alabama • Little Rock, Arkansas • Santa Rosa, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Sep 26, 2026, 2:12 PM EDT
Terminated Phase 1 Interventional Results available

Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin

NCT04163952
View directory record Official record
Conditions
Locally Advanced Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Recurrent Skin Squamous Cell Carcinoma
Interventions
Panitumumab, Talimogene Laherparepvec
Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
5
States / cities
New Brunswick, New Jersey • New York, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 26, 2026, 2:12 PM EDT
Completed Phase 2 Interventional Results available

A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma

NCT00289016
View directory record Official record
Conditions
Melanoma
Interventions
Talimogene Laherparepvec
Drug
Lead sponsor
BioVex Limited
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
7
States / cities
La Jolla, California • Los Angeles, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2015 · Synced Sep 26, 2026, 2:12 PM EDT
Completed Phase 1 Interventional

T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer

NCT03554044
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Breast Carcinoma
Interventions
Anastrozole, Exemestane, Fulvestrant, Letrozole, Paclitaxel, Talimogene Laherparepvec, Tamoxifen, Nab paclitaxel, Gemcitabine, Carboplatin
Drug · Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Sep 26, 2026, 2:12 PM EDT
No Longer Available No phase listed Expanded access

Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma

NCT02147951
View directory record Official record
Conditions
Unresected Stage IIIb to IVM1c Melanoma
Interventions
Talimogene Laherparepvec
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 95 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
24
States / cities
Mobile, Alabama • Little Rock, Arkansas • Duarte, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Sep 26, 2026, 2:12 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

TVEC and Preop Radiation for Sarcoma (8 ml Dose)

NCT04599062
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Talimogene Laherparepvec, Radiotherapy
Drug · Radiation
Lead sponsor
John Rieth
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Sep 26, 2026, 2:12 PM EDT
Completed Phase 1 Interventional Results available

Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors

NCT02756845
View directory record Official record
Conditions
Advanced Non CNS Tumors
Interventions
Talimogene Laherparepvec
Drug
Lead sponsor
Amgen
Industry
Eligibility
2 Years to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
9
States / cities
Wilmington, Delaware • Jacksonville, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Sep 26, 2026, 2:12 PM EDT
Withdrawn Phase 2 Interventional

Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma

NCT03972046
View directory record Official record
Conditions
Melanoma (Skin), Melanoma Stage IIIb-IVM1a, Metastasis Skin, Tumor Skin, BRAF Gene Mutation
Interventions
Talimogene laherparepvec (T-Vec), Dabrafenib (BRAF Inhibitor), Trametinib (MEK Inhibitor)
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 26, 2026, 2:12 PM EDT
Terminated Phase 3 Interventional Results available

Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma

NCT02263508
View directory record Official record
Conditions
Melanoma
Interventions
Talimogene Laherparepvec, Pembrolizumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 95 Years
Enrollment
713 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
41
States / cities
Birmingham, Alabama • Mobile, Alabama • Beverly Hills, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Sep 26, 2026, 2:12 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma

NCT00769704
View directory record Official record
Conditions
Melanoma
Interventions
Talimogene laherparepvec, GM-CSF
Biological
Lead sponsor
BioVex Limited
Industry
Eligibility
18 Years and older
Enrollment
437 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
57
States / cities
Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Sep 26, 2026, 2:12 PM EDT
Terminated Phase 1 Interventional

Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted

NCT04185311
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, HER2/Neu Negative, Invasive Ductal Carcinoma, Not Otherwise Specified, Progesterone Receptor Negative, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions
Ipilimumab, Nivolumab, Talimogene Laherparepvec
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Sep 26, 2026, 2:12 PM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Combination Immunotherapy for Stage III Melanoma

NCT03842943
View directory record Official record
Conditions
Cutaneous Melanoma
Interventions
Pembrolizumab, Talimogene Laherparepvec
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Sep 26, 2026, 2:12 PM EDT
Completed Phase 1 Interventional Results available

Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137)

NCT02626000
View directory record Official record
Conditions
Carcinoma of the Head and Neck
Interventions
Talimogene Laherparepvec, Pembrolizumab
Drug · Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
Newark, Delaware • Chicago, Illinois • Louisville, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2021 · Synced Sep 26, 2026, 2:12 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

NCT03069378
View directory record Official record
Conditions
Sarcoma, Epithelioid Sarcoma, Cutaneous Angiosarcoma
Interventions
Talimogene Laherparepvec (T-VEC), Pembrolizumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
5
States / cities
Menlo Park, California • Stanford, California • Harrison, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 26, 2026, 2:12 PM EDT
Terminated Phase 2 Interventional Results available

Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery

NCT02658812
View directory record Official record
Conditions
Malignant Chest Wall Neoplasm, Recurrent Breast Carcinoma, Recurrent Inflammatory Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Inflammatory Breast Carcinoma
Interventions
Laboratory Biomarker Analysis, Talimogene Laherparepvec
Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2023 · Synced Sep 26, 2026, 2:12 PM EDT
Active, not recruiting Phase 2 Interventional

Neoadjuvant Intralesional Injection of Talimogene Laherparepvec

NCT06660810
View directory record Official record
Conditions
Soft Tissue Sarcoma, Sarcoma,Soft Tissue
Interventions
Talimogene Laherparepvec, Neoadjuvant Radiation, Surgery
Drug · Radiation · Procedure
Lead sponsor
John Rieth
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 26, 2026, 2:12 PM EDT
Completed No phase listed Observational

Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection

NCT02910557
View directory record Official record
Conditions
Melanoma, Herpetic Infection
Interventions
Not listed
Lead sponsor
Amgen
Industry
Eligibility
Not listed
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
9
States / cities
Coral Springs, Florida • Baltimore, Maryland • Jefferson City, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 26, 2026, 2:12 PM EDT